Patrick Zhang

AdvanCell is a clinical stage radiopharmaceutical company developing an innovative pipeline of 212Pb-based Targeted Alpha Therapies for cancer patients. AdvanCell’s platform technology addresses the most significant challenge in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell’s novel drug discovery, preclinical processes, and state-of-the-art facilities leverage daily access to 212Pb, the ideal isotope for Targeted Alpha Therapy. For more information, please visit www.advancell.com.au

Epia Neuro is a neural technology company developing intent-driven systems designed to restore function and independence for people living with neurological conditions. Its platform integrates implantable neural interfaces, adaptive algorithms, and assistive devices to translate neural intent into real-world action. The company’s initial focus is stroke-related motor impairment, with expansion in cognitive decline and other neurological disorders, focusing on long-term solutions for the growing aging population.

Unlocking deeper insights from empirical data in the pursuit of better medicines.

Accelerating molecular discovery through the power of Chemputation.

BioLoomics is a preclinical stage biotechnology company leveraging directed evolution of antibodies in human cells to create target degrading antibodies. Our proprietary tech combines single-cell bioassay engineering, robotics, and ML. #synbio #directedevolution #antibodies

Decoding Secreted Proteins for Chronic and Age-Related Diseases

Manifold Bio is a therapeutics company with an unprecedented advantage in engineering precision biologics. We have developed the world’s first high-throughput in vivo drug design platform, enabled by a novel protein barcoding technology and other innovations at the interface of molecular biology and compute. Our mission is to make the best life-saving drugs available to patients as quickly as possible. We’ve brought together a team with unique expertise in library-guided protein engineering combining DNA synthesis, sequencing, and advanced bioinformatics and machine learning. We’re growing and we’re looking for those who are excited about the potential of our novel approach to engineering biology.

Kelonia is pioneering a new wave of genetic medicines using its next generation gene delivery platform. The company’s simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. With an initial focus on developing transformational therapies for solid tumors and hematologic cancers, Kelonia is building a pipeline of genetic medicines for a wide range of diseases, with the bold goal of bringing genetic medicines to every patient in need.

Concerto Biosciences reinvents humanity’s relationship with microbes. We envision a future where each of us fine-tunes the microbial communities in us, on us, and around us to stay healthy. To pave the way, Concerto invented a platform to measure, in ultra-high throughput, how microbes behave in the presence of each other. These measurements enable Concerto to see the world as it is: a massive underlying network of microbial interactions that shapes the health of our bodies and our planet. The network reveals new products—“ensembles” of microbes that work in concert to perform tasks that benefit people. Our first ensembles rehabilitate the skin microbiome, providing protection from previously intractable diseases like eczema and restoring health to millions.

Theradaptive is developing a therapeutic delivery platform for multiple clinical indications including immuno-oncology, orthopedics and soft tissue repair.

A novel way to identify and sort cells. Our mission is to enable novel biological insights at the single-cell level for improved diagnosis and treatment of disease.

Our mission is to cure age-related disease by moving successful therapeutics toward clinical trials within months, not years. #CreatingTime

At Ansa Biotechnologies, we’re developing a way to synthesize DNA that will accelerate innovation in medicine, agriculture, and industrial biotechnology. Our fast, clean, and accurate enzymatic DNA synthesis process can produce gene-length molecules directly, overcoming bottlenecks of traditional DNA synthesis methods. We envision a future where our technology empowers scientists to develop solutions for the world's biggest problems in health and sustainability. Note that Ansa does not conduct any employment discussions via LinkedIn. All official Ansa career openings are exclusively listed on our website careers page.

Federation Bio is pioneering new platforms that target diseases in which the human microbiome can play a curative role. The company’s microbial approach leverages naturally occurring bacteria along with a diverse community of supportive bacteria to drive engraftment and durable therapeutic responses. This approach has potential in a diverse set of human conditions ranging from metabolic disorders and cholestatic diseases to cancer and autoimmune conditions. Federation Bio’s lead program is in secondary hyperoxaluria, a serious renal condition that affects more than 200,000 Americans and for which there are currently no approved therapies. Additional information can be found at www.federation.bio

Spiderwort Inc. is a tissue engineering company specializing in the development of transformative biomaterials for repairing and regenerating tissues within the human body.

AdvanCell is a clinical stage radiopharmaceutical company developing an innovative pipeline of 212Pb-based Targeted Alpha Therapies for cancer patients. AdvanCell’s platform technology addresses the most significant challenge in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell’s novel drug discovery, preclinical processes, and state-of-the-art facilities leverage daily access to 212Pb, the ideal isotope for Targeted Alpha Therapy. For more information, please visit www.advancell.com.au

Epia Neuro is a neural technology company developing intent-driven systems designed to restore function and independence for people living with neurological conditions. Its platform integrates implantable neural interfaces, adaptive algorithms, and assistive devices to translate neural intent into real-world action. The company’s initial focus is stroke-related motor impairment, with expansion in cognitive decline and other neurological disorders, focusing on long-term solutions for the growing aging population.

HistoSonics is a growth phase company developing a non-invasive sonic beam therapy platform and procedure using the science of histotripsy. Histotripsy utilizes the pressure created by focused sound energy to liquefy and destroy targeted tissue, including diseased tissue and tumors, at sub-cellular levels. The company’s new platform delivers personalized, tissue specific treatments with precision and control, and without the undesirable side effects of many of today’s interventional and surgical modalities. HistoSonics is led by a team of experienced domain experts and industry leaders with offices in Ann Arbor, MI, Madison, WI, and Minneapolis, MN.

Unlocking deeper insights from empirical data in the pursuit of better medicines.

Accelerating molecular discovery through the power of Chemputation.